Published in Cancer Weekly, March 7th, 2006
Revenue recognized from sales of the NMP22 BladderChek Test increased 38% during the quarter to $2,254,000 compared to $1,632,000 in the fourth quarter of 2004. Overall product sales for the fourth quarter of 2005 were $2,776,000 compared with $2,382,000 for the fourth quarter of 2004. NMP22 BladderChek Test sales accounted for approximately 90% of sales in the NMP22 product line.
The company reported a loss from operations of $1,795,000 for the fourth quarter of 2005 compared with a loss from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.